A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Protocol No
EXELIXIS-XL092-002
Phase
I
Summary

This project is being done to evaluate potential new anticancer therapies with advanced solid tumors. The study will provide information about the safety, ability of the body to accept the drug(s), the amount of drug(s) and/or break down products in the blood and the body's reaction to the drug(s).

Description
A Dose-Escalation Study of XL092 in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Colorectal, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers
ClinicalTrials.gov
go to website